Tiziana Life Sciences Plc Release: Interim Results For The Six Months Ended 30 June 2014

A Transformative Year

London, 30 September 2014 – Tiziana Life Sciences (AIM: TILS), a biotechnology company in the fight against metastatic cancers, today announces its interim results for the six months ended 30 June 2014.

Highlights

• Joined the AIM market of the London Stock Exchange on 24 April 2014 under the ticker symbol TILS
• £2m raised through a placing completing the reverse acquisition of Alexander David Investments plc by Tiziana Pharma Ltd; additional £0.73m raised through a convertible loan note
• Further £1.45m raised through convertible loan note issued on 17 June 2014
• Licensing agreement with TTFactor S.r.l. to develop stem cell based breast cancer diagnostics
• Professor Pier Paolo Di Fiore, inventor of the gene expression signature the TOP 20 model, appointed to Scientific Advisory Board
• Dr Napoleone Ferrara, whose research led to the development of drugs Avastin® and Lucentis®, appointed as Chairman of the Scientific Advisory Board
• For the six months to 30 June 2014 the consolidated Group made a loss of £1.57m
• The Group ended the period with £3.55m cash as at 30 June 2014

Post Period Highlights

• Professor Roberto Pellicciari, co-founder and current Head of Medicinal Chemistry at Intercept Pharmaceuticals (NASDAQ: ICPT), appointed to Scientific Advisory Board

Commenting on the results, Gabriele Cerrone, Executive Chairman of Tiziana, said: “The past few months have been transformative for Tiziana. The successful completion of the reverse acquisition of Alexander David Investments plc and the funds raised to date will enable us to build on the success of our current pre-clinical programmes. With our Scientific Advisory Board now comprising of Dr Ferrara as Chairman, Prof Di Fiore and Prof Pellicciari, we have significant breadth and depth of knowledge in the field of oncology. We are confident that we are well-placed to become a leading player in developing novel molecules that will improve the quality of life for patients with metastatic breast cancer.”

Contacts:

Tiziana Life Sciences plc
Philip Boyd
+44 (0)20 7493 2853

Cairn Financial Advisers LLP
Nominated Advisor
Liam Murray / Avi Robinson
+44 (0)20 7148 7900

Beaufort Securities Limited
Broker
Saif Janjua
+44 (0)20 7382 8300

FTI Consulting
Simon Conway
+44 (0)20 3727 1000

About Tiziana Life Sciences

Tiziana Life Sciences plc is a biotechnology company that focuses on the discovery and development of novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers.

Tiziana Life Sciences’ research team is directly attributed with the discovery that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be the regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in the more aggressive breast cancers, but across the whole clinical spectrum of breast disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news